SuperworthArrowhead Pharmaceuticals shares outstanding ARWR
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 143.4M
- On a year earlier
- +3.1%
- more shares
Arrowhead Pharmaceuticals had 143.4M diluted shares outstanding on average in Q3 FY26, the quarter to Jun 30, 2026.
That is 3.1% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 137.8M | +11% |
| FY2024 | 124.3M | +16% |
| FY2023 | 107.2M | +1% |
| FY2022 | 105.9M | +2% |
| FY2021 | 104.3M | +2% |
| FY2020 | 102.3M | +1% |
| FY2019 | 101M | +15% |
| FY2018 | 88.1M | +18% |
| FY2017 | 74.8M | +15% |
| FY2016 | 64.9M | +9% |
| FY2015 | 59.5M | +10% |
| FY2014 | 54M | +38% |
| FY2013 | 39.2M | +214% |
| FY2012 | 12.5M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q3 FY26 | 143.4M | +3% | |
| Q2 FY26 | 142.4M | +6% | |
| Q1 FY26 | 140.7M | +13% | |
| Q4 FY25 | 137.8M | +11% | |
| Q3 FY25 | 139M | +12% | |
| Q2 FY25 | 134.5M | +9% | |
| Q1 FY25 | 124.8M | +16% | |
| Q4 FY24 | 124.3M | +16% | |
| Q3 FY24 | 124.2M | +16% | |
| Q2 FY24 | 123.3M | +14% | |
| Q1 FY24 | 107.4M | +1% | |
| Q4 FY23 | 107.2M | +1% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Arrowhead Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.